Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

CONTEXT: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Endocrinol Metab
Hlavní autoři: Tsai, Joy N., Zhu, Yuli, Foley, Katelyn, Lee, Hang, Burnett-Bowie, Sherri-Ann, Neer, Robert M., Leder, Benjamin Z.
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2015
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5393530/
https://ncbi.nlm.nih.gov/pubmed/25933031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1541
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky